Introducing our new CEO & President: Eugene Ciolfi


We are pleased to announce that Eugene Ciolfi has joined as its President and Chief Executive Officer. In conjunction with his hiring, he has also been appointed to MedPharm’s Board of Directors.

Gene joins MedPharm with over 25 years of experience in the development and manufacturing of pharmaceutical drug products in semi-solid, liquid and other, alternative dosage forms. His previous experience includes having served in a variety of manufacturing, commercial operations and general management positions at DPT Laboratories. Most recently, for the past two years, Gene served as Site Head of Torrent Pharma’s FDA/DEA Class II-V approved non-sterile liquid and semi-solid development and manufacturing operation.

CEO Eugene CiolfiGene is charged with driving MedPharm’s growth further downstream into commercial manufacturing and opening up additional markets based on the company’s unique performance modelling, formulation development and manufacturing expertise.

Dr. Andy Muddle, Co-founder of MedPharm who has served as its CEO for the past 19 years, will remain with the Company in an ambassadorial role. He has been actively involved in many of the decisions that have been fundamental to MedPharm’s success. Dr. Muddle will continue to provide support to the commercial team and remain focused on strategy and commercial development, in addition to continuing to serve on the Company’s Board of Directors.

Professor Marc Brown, Co-founder and Chief Scientific Officer commented, “MedPharm’s unique position in the topical and transdermal formulation development arena, along with Gene’s know-how and experience, makes for a winning combination. I would like to congratulate him as he steps into his new role, and we look forward to supporting him as he expands MedPharm’s offering.”

Ampersand General Partner and MedPharm Board Member David Parker added “Gene’s decades of relevant industry experience and impressive track record make him ideally suited for the MedPharm CEO position. We are extremely pleased that he will be leading the Company as it moves to expand its manufacturing capabilities and deliver on its ambitious growth plans.”

Notes to editors

About MedPharm
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centres in the USA and UK and has its global HQ in Guildford, UK.

About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories. Additional information about Ampersand is available at www.ampersandcapital.com.